UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 9, 2021
GENETHERA, INC.
(Exact name of registrant as specified in its charter)
Nevada | 000-27237 | 65-0622463 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
3051 W 105th Ave. Westminster, CO | 80031 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (720) 587-5100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
ITEM 1.01 GENETHERA, INC. AND CUMMING MANAGEMENT GROUP, INC. ENTERED INTO A CONSULTING AGREEMENT
On April 9, 2021 GeneThera Inc. entered into a consulting agreement with Cumming Management Group, Inc. According to the terms on the agreement, Cumming will provide support services related to the construction of GeneThera’s Biosafety Level 3 (BSL-3) laboratory facilities to be used as molecular robotic diagnostic therapeutic and research facilities for SARS-CoV-2 and other zoonotic diseases. Scope of the services and fees are outlined in Exhibit A and B attached to the Consulting Agreement. GeneThera will proceed with Cumming as its sole consulting services provider for the related BSL-3 Lab project.
Item 9.01 EXHIBITS
Exhibit Number | Description |
10.1 | Collaboration Agreement |
Exhibit A |
Exhibit B |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
GeneThera, Inc., | |
a Nevada Corporation | |
By:/s/ Antonio Milici | |
Antonio Milici, CEO |
Date: April 27, 2021
3